EAU 2013 - Programme Book - YouMed

Monday, 18 March - EAU Programme
Abstract Session
09.15 - 10.45 Management of high risk prostate cancer
Brown Hall 1-2 - Level S2
Poster Session 57
Chairs: M. Ramirez Backhaus, Valencia (ES)
T. Wiegel, Ulm (DE)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
685 Risk-factors for biochemical recurrence- and clinical metastasis-free survival in D’Amico high-risk patients
after radical prostatectomy
A. Becker, P. Tennstedt, T. Steuber, M. Graefen, H. Heinzer (Hamburg, Germany)
* 686 Association between time to biochemical recurrence and cancer specific and other cause mortality in men
with high risk prostate cancer treated with radical prostatectomy without adjuvant treatments. A multiinstitutional
analysis
M. Bianchi, J.R. Karnes, S. Joniau, M. Spahn, P. Gontero, F.K. Chun, J. Hansen, G. Marchioro, F. Abdollah,
B. Tombal, U. Capitanio, P. Bastian, H. Van Der Poel, R. Sanchez-Salas, A. Briganti (Milan, Turin, Novara,
Italy; Rochester, United States of America; Leuven, Brussels, Belgium; Berne, Switzerland; Hamburg,
Munich, Germany; Amsterdam, The Netherlands; Paris, France)
687 A competing-risks analysis of survival after alternative treatment modalities for locally advanced prostate
cancer patients: A population-based study
F. Abdollah, M. Bianchi, N.M. Passoni, A. Nini, P. Dell’Oglio, S. Corti, R. Colombo, C. Cozzarini, R. Damiano,
N. Di Muzio, M. Sun, A. Briganti (Milan, Catanzaro, Italy; Montreal, Canada)
* 688 Predicting prostate cancer specific outcome after radical prostatectomy among men with (very) high-risk,
locally advanced PCa with or without additional high risk factors: A multi-institutional retrospective cohort
study of 1644 patients
S. Joniau, A.R. Alberts, F. Moltzahn, A. Briganti, J. Karnes, P. Gontero, E. Weyne, C-Y. Hsu, G. Marchioro,
B. Tombal, J. Chun, P. Bastian, H. Van Der Poel, R. Sanchez-Salas, M. Spahn (Leuven, Brussels, Belgium;
Berne, Switzerland; Milan, Turin, Novara, Italy; Rochester, United States of America; Puli, Taiwan; Hamburg,
Munich, Germany; Amsterdam, The Netherlands; Paris, France)
689 Impact of surgery delay in patients diagnosed with high grade prostate cancer
S. Samavedi, H. Abdul-Muhsin, O. Schatloff, K. Palmer, G. Ebra, V. Patel (Celebration, United States of
America)
690 Can immediate adjuvant therapy be avoided in patients with prostate specimen Gleason ≥ 8, organ
confined disease, absence of positive lymph nodes and surgical margins, who undergo robot-assisted
laparoscopic radical prostatectomy?
A.P. Labanaris, V. Zugor, J.H. Witt (Gronau, Germany)
691 Comparison of the survival rate between prostate cancer patients with Gleason score 8 and those with
score 9 or higher for different therapeutic approaches
H.K. Ha, J.Y. Ku, J.H. Ahn, S.M. Kang, C.H. Lee, S.D. Kim, T.S. Kim, J.H. Yoon, M.K. Chung, D.S. Kim,
J.M. Chung, J.Z. Lee (Busan, South Korea)
692 Radio-guided surgery: Our experience in sentinel lymph node removal in prostate cancer
M. Grasso, S. Blanco, A.A.C. Grasso, G. Bovo, A. Crespi, M. Arosio (Monza, Milan, Italy)
EAU Milan 2013
237
Monday